The risk and outcomes of pneumonia in patients on inhaled corticosteroids

Pulm Pharmacol Ther. 2015 Jun:32:130-6. doi: 10.1016/j.pupt.2015.04.001. Epub 2015 May 5.

Abstract

Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICS are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

Keywords: Chronic obstructive pulmonary disease; Inhaled corticosteroids; Pneumonia.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Administration, Inhalation
  • Asthma / drug therapy
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / adverse effects*
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects*
  • Humans
  • Pneumonia / chemically induced*
  • Pneumonia / epidemiology
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Quality of Life
  • Risk

Substances

  • Bronchodilator Agents
  • Glucocorticoids